Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

<< Previous

Bullboard Posts

Next >>

Post by Duster340on Jan 26, 2024 12:12pm

275 Views

Post# 35847208

More updates

coming soon with the financials in about 2 weeks time, i think march will be the next of "several" in the series of " a conversation with antibe" when they will announce that P2 is underway. they must be planning on keeping shareholders updated on the latest with these conversations, will the third one be during P2 ?
as for the warrants i would be surprised if all or close to all were not exercised. 6M to 6.5M cash added. 2.5 days was more than enough time for the warrants to be exercised. clearly it looks like the arbitration has been kicked down the road because if all goes well there may be a new deal in the works with nuance.

<< Previous

Bullboard Posts

Next >>

High Tide adds two stores to undervalued cannabis retail network